Corvus Pharmaceuticals, Inc. (CRVS)

Corvus Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	18.91	4.58	8.74	12.62	13.16	63.46
Short-Term Investments	196.32	52.17	43.22	14.53	29.14	5.99
Cash & Short-Term Investments	215.23	56.75	51.96	27.15	42.3	69.45
Cash Growth	189.26%	9.21%	91.40%	-35.82%	-39.09%	56.92%
Accounts Receivable	0.01	0.04	0.08	0.03	0.59	0.51
Other Receivables	1.84	0.34	0.14	0.04	0.05	0.03
Receivables	1.85	0.37	0.22	0.06	0.63	0.54
Prepaid Expenses	0.39	0.17	0.47	0.38	0.43	0.45
Other Current Assets	3.49	0.92	1.76	0.37	0.29	0.87
Total Current Assets	220.97	58.21	54.41	27.96	43.66	71.31
Property, Plant & Equipment	1.49	1.06	1.33	1.39	2.57	3.64
Long-Term Investments	15.11	10.99	12.54	16.12	21.88	34.27
Other Long-Term Assets	1.71	0.86	0.63	0.09	0.13	0.24
Total Assets	239.27	71.12	68.91	45.55	68.24	109.46

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	4.05	2.49	2.58	1.53	1.98	1.57
Accrued Expenses	8.87	6.25	3.44	3.73	7.39	6.96
Current Portion of Leases	0.45	0.4	0.19	1.37	1.23	1.05
Other Current Liabilities	0.3	0.24	29.2	0.25	0.16	0.12
Total Current Liabilities	13.67	9.38	35.4	6.87	10.75	9.69
Long-Term Leases	0.27	0.53	0.94	-	1.37	2.6
Total Liabilities	13.95	9.91	36.34	6.87	12.13	12.29

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0.01	0.01	0.01	0.01	0.01	0.01
Additional Paid-In Capital	670.56	474.39	430.86	374.36	364.36	361.67
Retained Earnings	-443.94	-412.29	-397.01	-334.72	-307.69	-266.38
Comprehensive Income & Other	-1.29	-0.9	-1.29	-0.97	-0.56	1.87
Total Common Equity	225.33	61.21	32.57	38.68	56.12	97.16
Shareholders' Equity	225.33	61.21	32.57	38.68	56.12	97.16
Total Liabilities & Equity	239.27	71.12	68.91	45.55	68.24	109.46

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	0.73	0.94	1.12	1.37	2.6	3.65
Net Cash (Debt)	214.5	55.81	50.84	25.78	39.7	65.8
Net Cash Growth	192.54%	9.78%	97.25%	-35.08%	-39.67%	56.87%
Net Cash Per Share	2.46	0.70	0.83	0.54	0.85	1.57
Filing Date Shares Outstanding	84.12	83.99	68.14	49.04	46.57	46.55
Total Common Shares Outstanding	84.12	74.7	67.9	49.04	46.55	46.55
Working Capital	207.29	48.83	19.01	21.09	32.91	61.62
Book Value Per Share	2.68	0.82	0.48	0.79	1.21	2.09
Tangible Book Value	225.33	61.21	32.57	38.68	56.12	97.16
Tangible Book Value Per Share	2.68	0.82	0.48	0.79	1.21	2.09
Machinery	3.21	2.84	2.69	2.85	2.82	2.62
Construction In Progress	0.3	-	-	-	-	-
Leasehold Improvements	0.03	0.03	2.08	2.08	2.08	2.08

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Aug 6, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 25, 2026

Data Sources Report a data error